Talking HER2-Targeted Therapy With Dr. Ajani

We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies. Listen on to hear Ajani discuss some of the HER2-targeted strategies that are under exploration in gastric/GEJ cancer and colorectal cancer, the potential downsides of bulk tumor testing, and the promise of liquid biopsies in the space.